The pan janus kinase (JAK) inhibitor KN-002 suppresses inflammatory mediator release from severe asthma bronchial epithelial cells. Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Increased activity of Lyn tyrosine kinase causes multiple chronic obstructive pulmonary disease-like changes in mouse Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
Inhibition of Pim1 kinase, new therapeutic approach in virus-induced asthma exacerbations Source: Eur Respir J 2016; 47: 783-791 Year: 2016
Corticosteroid insensitivity and enhanced mitogen-activated protein kinase activity in airway smooth muscle cells of severe asthma Source: Annual Congress 2011 - Airway smooth muscle cells and fibroblasts: cell biology Year: 2011
Anti IL-17 with or without Rho kinase inhibitor in mice with chronic allergic pulmonary inflammation Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017
Effect of PDGF receptor tyrosine kinase inhibitor AG1296 on bleomycin-induced lung fibrosis in mice Source: Annual Congress 2004 - Pulmonary fibrosis - new insights Year: 2004
Regulation of calcineurin on protein kinases activities in asthmatic airway remodeling in guinea pig Source: Eur Respir J 2005; 26: Suppl. 49, 581s Year: 2005
Effect of anti-IL17 and/or Rho-kinase inhibitor treatments on vascular remodelling in an asthma model in mice Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets Year: 2019
Inhibition of VEGF blocks the activation of TGF-β1 through a PI3K/Akt signaling pathway in allergic airway disease of mice Source: Annual Congress 2007 - Current issues in airway physiology, pharmacology and monitoring Year: 2007
Ceramide-1-phosphate decreases allergic airway inflammation, remodeling and hyperresponsiveness by inhibition of phosphorilation of NF-kappa B, Akt, MAPK p-38 in dendritic cells Source: Annual Congress 2010 - Models of airways disease Year: 2010
Inhibition of P38 kinase does not reduce production of TNF-alpha from airway cells in COPD Source: Annual Congress 2007 - Epithelial networks in the airways Year: 2007
A dual role of IL-6 signalling and STAT-3 activation on airway inflammation versus airway hyperresponsiveness in a murine model of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 568s Year: 2002
MAP kinase phosphatase 1 mediates glucocorticoid inhibition of CD38 expression in human airway smooth muscle Source: Annual Congress 2008 - Basic science in asthma and COPD II Year: 2008
The p38 MAP kinase inhibitor dilmapimod ameliorates airway inflammation induced by ozone challenge in healthy volunteers Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use Year: 2012
The potent and lung-selective inhaled pan JAK inhibitor TD-8236 limits airway inflammation without affecting systemic immunity in mice Source: International Congress 2019 – Novel targets and mechanisms in asthma Year: 2019
Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018
Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma Source: Eur Respir J 2010; 35: 750-756 Year: 2010
Activated protein C inhibits bronchial inflammation and hyperresponsiveness in a mouse model of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 618s Year: 2002
PDGF and Src tyrosine kinases in pulmonary arterial smooth muscle cells: Effects of dasatinib and nilotinib on pulmonary vascular remodeling Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models Year: 2011